The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. [electronic resource]
Producer: 20071024Description: 13283-8 p. digitalISSN:- 0027-8424
- Animals
- Basophils -- drug effects
- Dasatinib
- Enzyme-Linked Immunosorbent Assay
- Fusion Proteins, bcr-abl
- Histamine Release -- drug effects
- Humans
- K562 Cells
- Mice
- Mice, Inbred C57BL
- Protein Kinase Inhibitors -- pharmacology
- Protein-Tyrosine Kinases -- antagonists & inhibitors
- Pyrimidines -- pharmacology
- Thiazoles -- pharmacology
- U937 Cells
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.